NCT02702492: PAK4 and NAMPT in Patients With Solid Malignancies or NHL (PANAMA)

NCT02702492
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: NAPRT1
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Serine-Threonine Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: NAPRT1 status is required for the dose escalation phase
Exclusions: 
https://ClinicalTrials.gov/show/NCT02702492

Comments are closed.

Up ↑